CTI 105
Alternative Names: CTI 111; CTI-105Latest Information Update: 27 Feb 2025
Price :
$50 *
At a glance
- Originator Cellics Therapeutics
- Class Anti-infectives; Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Sepsis
Most Recent Events
- 09 Dec 2024 CTI 105 is still in preclinical development for Sepsis in USA
- 28 Jul 2024 No recent reports of development identified for preclinical development in Sepsis in USA
- 23 Jun 2020 CTI 105 is available for licensing as of 23 Jun 2020. https://cellics.com/business-development/